These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 29498802)
1. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis. Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802 [TBL] [Abstract][Full Text] [Related]
2. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis. Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901 [TBL] [Abstract][Full Text] [Related]
3. BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL. Flores-Romero H; Landeta O; Ugarte-Uribe B; Cosentino K; García-Porras M; García-Sáez AJ; Basañez G Cell Death Differ; 2019 Oct; 26(10):1880-1894. PubMed ID: 30560933 [TBL] [Abstract][Full Text] [Related]
4. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis. Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981 [TBL] [Abstract][Full Text] [Related]
5. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380 [TBL] [Abstract][Full Text] [Related]
6. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213 [TBL] [Abstract][Full Text] [Related]
7. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells. Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775 [TBL] [Abstract][Full Text] [Related]
8. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Kelly PN; Puthalakath H; Adams JM; Strasser A Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859 [TBL] [Abstract][Full Text] [Related]
9. Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells. Kim WI; Wiesner SM; Largaespada DA Exp Hematol; 2007 Aug; 35(8):1231-9. PubMed ID: 17560009 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of the antiapoptotic Bcl-2 family member A1/Bfl-1 protects mice from anaphylaxis. Ottina E; Lyberg K; Sochalska M; Villunger A; Nilsson GP J Immunol; 2015 Feb; 194(3):1316-22. PubMed ID: 25548219 [TBL] [Abstract][Full Text] [Related]
18. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984 [TBL] [Abstract][Full Text] [Related]
19. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886 [TBL] [Abstract][Full Text] [Related]